A landmark study of 2.3 million women reveals critical insights into the broader health benefits of GLP-1 medications. Clinicians should note three key findings: women using these drugs experienced a 17% reduction in breast cancer risk, those who developed breast cancer had 24% lower mortality rates, and protective effects were greatest in postmenopausal women with BMI exceeding 35. These findings suggest that GLP-1 receptor agonists may offer cancer prevention benefits alongside their established weight-loss and glycemic control effects. For patients already taking these medications for diabetes or weight management, these results provide additional reassurance about safety and potential protective value. However, patients should not initiate GLP-1 therapy solely for cancer prevention; rather, these findings support their use in appropriate candidates seeking metabolic improvement.
Was this article helpful?
